International Hypertension Guidelines in CKD: ESH, ESC, KDIGO, and AHA/ACC Compared
This narrative review maps where the four major hypertension guidelines converge and diverge for CKD patients, clarifying practical implications for BP targets, RAS inhibition, diuretic selection, and cardio-renal add-on therapies.
Navigating global hypertension guidelines in CKD can enhance patient care.
Hypertension management in chronic kidney disease (CKD) is crucial due to the increased cardiovascular risk associated with condition severity. Guidelines agree on dual-agent therapy using renin-angiotensin system inhibitors with either calcium-channel blockers or diuretics, emphasizing the consideration of renal function in therapy selection. Clinicians must navigate varying global guidelines on hypertension in CKD, focusing on a patient-centered and cardio-renal protective approach. Understanding diverse guideline recommendations aids in optimizing hypertension management for CKD patients.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Stambolliu E, Stathopoulou E, Bora M, Damianaki A
Citation:Stambolliu E, Stathopoulou E, Bora M, et al. Hypertension in chronic kidney disease: where do international guidelines converge and diverge?. Clinical hypertension. 2026;32:e32. doi:10.5646/ch.2026.32.e32